ibritumomab tiuxetan   Click here for help

GtoPdb Ligand ID: 6777

Synonyms: IDEC-2B8 | IDEC-Y2B8-yttrium ibritumomab tiuxetan | NSC-715848 | Zevalin®
Approved drug Immunopharmacology Ligand
ibritumomab tiuxetan is an approved drug (FDA (2002), EMA (2004))
Compound class: Antibody
Comment: A monoclonal antibody used as a radioimmunotherapy treatment.
Immunopharmacology Disease
Disease X-Refs Comment References
non-Hodgkin lymphoma Disease Ontology: DOID:0060060
OMIM: 605027
Approved specifically for relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma can be treated with Yttrium-90 labelled ibritumomab tiuxetan.